Literature DB >> 26710333

Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention.

Hirokazu Konishi1, Katsumi Miyauchi2, Shuta Tsuboi1, Manabu Ogita1, Ryo Naito1, Tomotaka Dohi1, Takatoshi Kasai1, Hiroshi Tamura1, Shinya Okazaki1, Kikuo Isoda1, Hiroyuki Daida1.   

Abstract

BACKGROUND: Chronic kidney disease (CKD) is associated with increased risk for cardiovascular disease. The predictive power of traditional risk factors for cardiovascular disease is diminished in patients with CKD. The serum level of lipoprotein(a) [Lp(a)] can be a risk factor for adverse events, but the clinical implications of Lp(a) in patients with CKD who have been treated by percutaneous coronary intervention (PCI) remain uncertain. We aimed to determine the role of Lp(a) on long-term outcomes in patients with CKD after PCI.
METHODS: We analyzed data from 904 patients with CKD among 3508 patients who underwent a first PCI between 1997 and 2011 at our institution. We divided patients into 2 groups [high (n=454) or low (n=450)] according to median levels of Lp(a). The primary outcome was a composite of all-cause death and acute coronary syndrome (ACS).
RESULTS: The baseline characteristics of the groups were similar and the median follow-up period was 4.7 years. Cumulative event-free survival was significantly worse for the group with high, than low Lp(a) (P=0.01). Multivariable analysis indicated a high Lp(a) level as an independent predictor of primary outcomes (hazard ratio, 1.35; 95% CI, 1.01-1.82; P=0.04).
CONCLUSIONS: A high Lp(a) value is associated with a poor prognosis after PCI for patients with CKD.
Copyright © 2015. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Chronic kidney disease; Lipoprotein(a); Percutaneous coronary intervention

Mesh:

Substances:

Year:  2015        PMID: 26710333     DOI: 10.1016/j.ijcard.2015.12.007

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

Review 1.  The effect of chronic kidney disease on lipid metabolism.

Authors:  Neris Dincer; Tuncay Dagel; Baris Afsar; Adrian Covic; Alberto Ortiz; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2018-12-05       Impact factor: 2.370

2.  Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting.

Authors:  BinBin Zheng-Lin; Alberto Ortiz
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

3.  Lipoprotein(a) and Risk of Myocardial Infarction and Death in Chronic Kidney Disease: Findings From the CRIC Study (Chronic Renal Insufficiency Cohort).

Authors:  Archna Bajaj; Scott M Damrauer; Amanda H Anderson; Dawei Xie; Matthew J Budoff; Alan S Go; Jiang He; James P Lash; Akinlolu Ojo; Wendy S Post; Mahboob Rahman; Muredach P Reilly; Danish Saleheen; Raymond R Townsend; Jinbo Chen; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-08-24       Impact factor: 8.311

Review 4.  Lipoprotein(a) in nephrological patients.

Authors:  Bernd Hohenstein
Journal:  Clin Res Cardiol Suppl       Date:  2017-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.